Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis
To know if stool transplant from a healthy person into an ulcerative colitis patient can help treat the disease.
To know if stool transplant from a healthy person into an ulcerative colitis patient can help treat the disease.
To better understand the genetic changes that make children susceptible to the development of autism spectrum disorder, and to study how these changes influence clinical outcomes.
To investigate the connection between diet, genetics, and diseases in Hispanic / Latino youth.
To improve patient care and achieve the best health outcomes possible for children with IBD.
The purpose of the study is to collect information from children 0-18 years of age with all types of pancreatitis to determine the number of children diagnosed with this condition, understand the causes and progression of the disease, and review laboratory and imaging findings as well as responses to any treatments given.
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
To find out the effects of a chemical in Stevia on the symptoms of NAFLD.
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.